RxDoctor Payments Data

Naykala Ruse, MD

Internal Medicine · Cullman, ALNPI 1467497339

Payments from drug & device makers

$4,502in general payments, 2019–2025

Across 269 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$454
  • Pfizer$375
  • GSK$299
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$177
  • Astellas Pharma US Inc$162
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$4,502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,502 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$138,898
Medicare patients
182
Services billed
8,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide104$125,033
OzempicSemaglutide73$89,987
TrulicityDulaglutide38$40,068
JardianceEmpagliflozin32$40,033
JanuviaSitagliptin Phosphate43$39,746
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$38,314
FarxigaDapagliflozin Propanediol42$31,695
Symlinpen 120Pramlintide Acetate11$25,972
Tresiba Flextouch U-200Insulin Degludec22$17,042
RybelsusSemaglutide11$15,522
EliquisApixaban24$15,396
GemtesaVibegron17$14,241
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$12,379
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,056
VascepaIcosapent Ethyl14$5,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,291$108,81297 claims
Boehringer IngelheimJardiance$55$40,03332 claims
AstraZenecaFarxiga, Breztri Aerosphere$64$39,75155 claims
MerckJanuvia$12$39,74643 claims
GSKTrelegy Ellipta$299$38,31453 claims
PfizerEliquis$375$15,39624 claims
Sumitomo Pharma America, Inc.Gemtesa$30$14,24117 claims
AbbVieSynthroid$454$1,28612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Cullman

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →